ReviewJMA journal2025
Clinical Application of Artificial Intelligence in Ultrasound Imaging for Oncology.
Review in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Implementing generative artificial intelligence in precision oncology: safety, governance, and significance.Journal of hematology & oncology · 2026Review
- Ultrasonography of Widespread Metastases in Advanced Gastric Signet Ring Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Artificial Intelligence-Based Software as a Medical Device (AI-SaMD): A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Research progress of artificial intelligence in the early screening, diagnosis, precise treatment and prognosis prediction of three central gynecological malignancies.Frontiers in oncology · 2025Review
- Artificial intelligence in modern clinical practice (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound (US) imaging is a widely used tool in oncology because of its noninvasiveness and real-time performance. However, its diagnostic accuracy can be limited by the skills of the examiner when performing manual scanning and by the presence of acoustic shadows that degrade image quality. Artificial intelligence (AI) technologies can support examiners in cancer screening and diagnosis by addressing these limitations. Here, we examine recent advances in AI research and development for US imaging in oncology. Breast cancer has been the most extensively studied cancer, with research predominantly focusing on tumor detection, differentiation between benign and malignant lesions, and prediction of lymph node metastasis. The American College of Radiology developed a medical imaging reporting and data system for various cancers that is often used to evaluate the accuracy of AI models. We will also explore the application of AI in clinical settings for US imaging in oncology. Despite progress, the number of approved AI-equipped software as medical devices for US imaging remains limited in Japan, the United States, and Europe. Practical issues that need to be addressed for clinical application include domain shifts, black boxes, and acoustic shadows. To address these issues, advances in image quality control, AI explainability, and preprocessing of acoustic shadows are essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.